IL4 Cancer Research Results

IL4, interleukin 4: Click to Expand ⟱
Source:
Type:
A cytokine that regulates humoral and adaptive immunity, and is involved in allergies and regulates inflammation.
IL-4 produced by cancer cells promotes resistance to immune checkpoint blockade (ICB). The close correlation between interleukin-4 (IL-4) and tumor progression has been observed in plenty of studies.

IL-4 is expressed in various cancers, including breast cancer, lung cancer, colorectal cancer, and hematological malignancies. Its expression can vary depending on the tumor type and the immune context.
Elevated levels of IL-4 are often associated with the presence of tumor-infiltrating immune cells, particularly Th2 cells and other immune cells that produce IL-4.
IL-4 is often considered a pro-tumorigenic cytokine. It can promote tumor growth and survival by enhancing the proliferation and survival of cancer cells. IL-4 can activate signaling pathways such as the STAT6 pathway, which is associated with cell proliferation and survival.
In some cancers, IL-4 can also promote angiogenesis, the formation of new blood vessels, which is critical for tumor growth and metastasis.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
560- ART/DHA,    Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo
- in-vivo, NA, NA
IL4↓, CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓,
3314- SIL,    Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review
- Review, NA, NA
*antiOx↑, *hepatoP↑, *Half-Life↑, *ROS↓, *GSH↑, *hepatoP↑, *lipid-P↓, *TNF-α↓, *IFN-γ↓, *IL2↓, *IL4↓, *NF-kB↓, *iNOS↓, *OATPs↓, *OCT4↓, *Inflam↓, *PGE2↓, MMPs↓, VEGF↓, angioG↓, STAT3↓, *ALAT↓, *AST↓, Dose↝,
3646- SIL,    "Silymarin", a promising pharmacological agent for treatment of diseases
- Review, NA, NA
*P-gp↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Cyt‑c↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

STAT3↓, 1,  

Migration ⓘ

MMPs↓, 1,   Treg lymp↓, 1,   TumCP↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD25+↓, 1,   CD4+↓, 1,   FoxP3+↓, 1,   IL4↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   GSH↑, 2,   lipid-P↓, 1,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 2,  

Cell Death ⓘ

iNOS↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

OCT4↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   OATPs↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 2,   IL10↓, 1,   IL2↓, 1,   IL4↓, 2,   Inflam↓, 2,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   Half-Life↓, 1,   Half-Life↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   AST↓, 2,  

Functional Outcomes ⓘ

hepatoP↑, 3,   RenoP↑, 1,  
Total Targets: 26

Scientific Paper Hit Count for: IL4, interleukin 4
2 Silymarin (Milk Thistle) silibinin
1 Artemisinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:561  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page